BioSpace News Archive

Business

Eyenovia to Report Fourth Quarter and Full-Year 2022 Results on Thursday, March 30

Eyenovia, Inc. today announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2022 on Thursday, March 30, 2023, after the markets close.

March 23, 2023
·
1 min read
Business

Palisade Bio Reports Year End 2022 Financial Results and Provides Corporate Update

Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today reported its financial results for the full year 2022 and provided a corporate update.

March 23, 2023
·
11 min read
Biotech Beach

Nexcella Announces New Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in AL Amyloidosis Patients + Additional Positive Multiple Myeloma Safety Data Demonstrating NXC-201 Outpatient CAR-T Treatment Potential

Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. announced that NXC-201 treatment continues to demonstrate 100% complete hematologic responses and 100% organ response rate – cardiac, renal, liver response – in a total of 8 AL amyloidosis patients.

March 23, 2023
·
8 min read
BioForest

Chinook Therapeutics Announces Upcoming Presentations at ISN World Congress of Nephrology 2023

Chinook Therapeutics, Inc. today announced presentations at the ISN World Congress of Nephrology 2023 from March 30 – April 2, 2023 in Bangkok, Thailand.

March 23, 2023
·
3 min read
Business

Jasper Therapeutics Appoints Daniel Adelman, M.D., as Acting Chief Medical Officer

Jasper Therapeutics, Inc. today announced the appointment of Daniel Adelman, M.D., as the company’s Acting Chief Medical Officer.

March 23, 2023
·
6 min read
BioMidwest

EVERSANA® Announces Partnership with ChemoMouthpiece, LLC to Support U.S. Launch & Commercialization of Medical Device to Help Cancer Patients Manage and Treat Oral Mucositis

EVERSANA® announced a partnership with ChemoMouthpiece, LLC to support the launch and commercialization of its medical device, the Chemo Mouthpiece™, to assist oncology patients across the United States.

March 23, 2023
·
4 min read
Policy

Creative Medical Technology Files Orphan Drug Designation Application with the U.S. FDA Using the ImmCelz® Platform for the Treatment of Brittle Type 1 Diabetes

Creative Medical Technology Holdings, Inc. announced that it filed an application with the U.S. Food and Drug Administration to receive Orphan Drug Designation for the treatment of Brittle Type 1 Diabetes using its ImmCelz® platform.

March 23, 2023
·
5 min read
Business

Establishment Labs Announces First Mia Femtech™ Partners in Europe and Second Partner Chain in Japan

Establishment Labs Holdings Inc. today announced it has entered into agreements with four partners in Europe and a second partner chain in Japan for Mia Femtech™ (“Mia®”).

March 23, 2023
·
6 min read
Drug Development

OliX Pharmaceuticals Receives Regulatory Approval to Commence Phase 1 Clinical Trial of Treatment of Androgenic Alopecia

OliX Pharmaceuticals, Inc. announced today that it has eceived approval from the Human Research Ethics Committee (HREC) in Australia to initiate a Phase 1 clinical trial of OLX72021, a treatment for androgenic alopecia, also known as male-pattern baldness.

March 23, 2023
·
3 min read
Pharm Country

Lisata Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call on Thursday, March 30, 2023, at 4:30 p.m. Eastern Time

Lisata Therapeutics, Inc. today announced that the Company will report its financial results for the three and twelve months ended December 31, 2022, on Thursday, March 30, 2023, after the close of trading and will host a conference call at 4:30 p.m. Eastern time.

March 23, 2023
·
2 min read